» Articles » PMID: 35583706

External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2022 May 18
PMID 35583706
Authors
Affiliations
Soon will be listed here.
Abstract

Medullary thyroid carcinoma (MTC) is a rare thyroid carcinoma with a variable clinical behavior. Potential clinical and pathological prognostic markers have been investigated, but studies are limited and controversial. In neuroendocrine neoplasms of various other sites, necrosis and proliferation (mitotic activity and/or Ki67 index) are integrated to provide a histological grade. Recently, an International Medullary Thyroid Carcinoma Grading System (IMTCGS) has been designed to define high- or low-grade MTC by combining proliferative activity and necrosis. This proposal integrates two previously published grading schemes by American (2-tiered grading, low- and high-grade MTC) and Australian authors (3-tiered grading, low-, intermediate-, and high-grade MTC). To validate the clinical role of these systems, their prognostic impact was evaluated in an independent cohort of 111 MTCs. Necrosis, which was the only parameter integrated into the 3 grading systems, proved to be individually correlate with tumor relapse, while no association was found with the proliferation (mitotic count and Ki67 index); however, by combining the different parameters according to all three grading systems, "high-grade" MTCs turned out to be significantly associated with the disease recurrence (p < 0.005) in all systems. In disease-free survival analysis, the IMTCGS stratification was the only one that demonstrated a significant impact at Cox regression analysis (p = 0.004), further confirmed by the Kaplan-Meier curves (p = 0.002). Similar findings were also reproduced when analysis was restricted to sporadic MTCs (68 cases). In conclusion, our results confirm the prognostic role of IMTCGS, supporting the importance of incorporating this information into the pathology report. However, none of the systems proved to predict the overall survival in this validation cohort.

Citing Articles

Validation of the International Medullary Thyroid Cancer Grading System and Identification of EZH2 as a Prognostic and Potential Therapeutic Marker in Medullary Thyroid Cancer.

Jager E, van Hemel B, Rutgers B, Zandee W, Jansen L, Kruijff S Cancers (Basel). 2025; 17(5).

PMID: 40075585 PMC: 11899120. DOI: 10.3390/cancers17050737.


Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.

Mete O, Boucher A, Schrader K, Abdel-Rahman O, Bahig H, Ho C Endocr Pathol. 2024; 35(4):293-308.

PMID: 39579327 PMC: 11659332. DOI: 10.1007/s12022-024-09836-x.


The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours.

Juhlin C J Clin Pathol. 2024; 78(1):1-10.

PMID: 38981664 PMC: 11671914. DOI: 10.1136/jcp-2023-209060.


Transcriptomic Differences in Medullary Thyroid Carcinoma According to Grade.

Ruz-Caracuel I, Caniego-Casas T, Alonso-Gordoa T, Carretero-Barrio I, Arino-Palao C, Santon A Endocr Pathol. 2024; 35(3):207-218.

PMID: 38958823 PMC: 11387449. DOI: 10.1007/s12022-024-09817-0.


International medullary thyroid carcinoma grading system: an Indian tertiary care centre experience.

Rai V, Saha A, Mehta S, Shah R, Trivedi P, Samanta S Eur Arch Otorhinolaryngol. 2023; 281(3):1571-1579.

PMID: 38010402 DOI: 10.1007/s00405-023-08341-x.


References
1.
Abraham D, Low T, Messina M, Jackson N, Gill A, Chou A . Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol. 2010; 18(1):219-25. DOI: 10.1245/s10434-010-1339-y. View

2.
van Veelen W, de Groot J, Acton D, Hofstra R, Hoppener J, Links T . Medullary thyroid carcinoma and biomarkers: past, present and future. J Intern Med. 2009; 266(1):126-40. DOI: 10.1111/j.1365-2796.2009.02106.x. View

3.
Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E . Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2007; 93(3):682-7. DOI: 10.1210/jc.2007-1714. View

4.
Moura M, Cavaco B, Leite V . RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer. 2015; 22(5):R235-52. DOI: 10.1530/ERC-15-0070. View

5.
Wells Jr S, Asa S, Dralle H, Elisei R, Evans D, Gagel R . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25(6):567-610. PMC: 4490627. DOI: 10.1089/thy.2014.0335. View